Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial

BACKGROUND: The mechanism through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) prevent the incidence of heart failure and/or affect cardiac structure and function remains unclear. METHODS: The EMPA-HEART trial is aimed at verifying whether empagliflozin improves myocardial contractility...

Descripción completa

Detalles Bibliográficos
Autores principales: Nesti, Lorenzo, Pugliese, Nicola Riccardo, Sciuto, Paolo, Trico, Domenico, Dardano, Angela, Baldi, Simona, Pinnola, Silvia, Fabiani, Iacopo, Di Bello, Vitantonio, Natali, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467417/
https://www.ncbi.nlm.nih.gov/pubmed/36096863
http://dx.doi.org/10.1186/s12933-022-01618-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467417/
https://www.ncbi.nlm.nih.gov/pubmed/36096863
http://dx.doi.org/10.1186/s12933-022-01618-1

Ejemplares similares